This is a happy day for all of us who were forcing ourselves to drink wine for the health benefits. According to the New York Times, GlaxoSmithKline, a British drugmaker, announced its plans to acquire a Cambridge, Mass. biotechnology company that is researching how compounds in wine retard aging, allowing us to live longer.  The scientists are aspiring to create a stronger, synthetic version of these compounds, assumedly so that it can be transformed into a drug.  Someday soon you will be able to reap all of those health benefits without the pesky enjoyment that accompanies actually drinking wine.